513 related articles for article (PubMed ID: 18606248)
1. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.
Humbert M; Montani D; Perros F; Dorfmüller P; Adnot S; Eddahibi S
Vascul Pharmacol; 2008; 49(4-6):113-8. PubMed ID: 18606248
[TBL] [Abstract][Full Text] [Related]
2. Cellular and molecular pathobiology of pulmonary arterial hypertension.
Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
[TBL] [Abstract][Full Text] [Related]
3. Current insights on the pathogenesis of pulmonary arterial hypertension.
Perros F; Dorfmüller P; Humbert M
Semin Respir Crit Care Med; 2005 Aug; 26(4):355-64. PubMed ID: 16121311
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
5. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
6. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia.
Eddahibi S; Guignabert C; Barlier-Mur AM; Dewachter L; Fadel E; Dartevelle P; Humbert M; Simonneau G; Hanoun N; Saurini F; Hamon M; Adnot S
Circulation; 2006 Apr; 113(15):1857-64. PubMed ID: 16606791
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension.
Tang EH; Vanhoutte PM
Physiol Genomics; 2008 Feb; 32(3):409-18. PubMed ID: 18056786
[TBL] [Abstract][Full Text] [Related]
8. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.
Tuder RM; Groves B; Badesch DB; Voelkel NF
Am J Pathol; 1994 Feb; 144(2):275-85. PubMed ID: 7508683
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells.
Damås JK; Otterdal K; Yndestad A; Aass H; Solum NO; Frøland SS; Simonsen S; Aukrust P; Andreassen AK
Circulation; 2004 Aug; 110(8):999-1005. PubMed ID: 15302794
[TBL] [Abstract][Full Text] [Related]
10. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
Oishi P; Datar SA; Fineman JR
Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Dumas de la Roque E; Savineau JP; Bonnet S
Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
[TBL] [Abstract][Full Text] [Related]
12. Endothelial progenitor cells in pulmonary arterial hypertension.
Diller GP; Thum T; Wilkins MR; Wharton J
Trends Cardiovasc Med; 2010 Jan; 20(1):22-9. PubMed ID: 20685574
[TBL] [Abstract][Full Text] [Related]
13. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.
Peled N; Shitrit D; Fox BD; Shlomi D; Amital A; Bendayan D; Kramer MR
J Rheumatol; 2009 May; 36(5):970-5. PubMed ID: 19369472
[TBL] [Abstract][Full Text] [Related]
14. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.
Dai Z; Li M; Wharton J; Zhu MM; Zhao YY
Circulation; 2016 Jun; 133(24):2447-58. PubMed ID: 27143681
[TBL] [Abstract][Full Text] [Related]
15. Endothelial dysfunction in pulmonary vascular disorders.
Stewart DJ
Arzneimittelforschung; 1994 Mar; 44(3A):451-4. PubMed ID: 8185722
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in vascular remodeling.
Schober A; Zernecke A
Thromb Haemost; 2007 May; 97(5):730-7. PubMed ID: 17479183
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension.
John J; Palevsky H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):197-205. PubMed ID: 22115402
[TBL] [Abstract][Full Text] [Related]
18. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets.
Mercier O; Sage E; de Perrot M; Tu L; Marcos E; Decante B; Baudet B; Hervé P; Dartevelle P; Eddahibi S; Fadel E
J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1538-46. PubMed ID: 19464477
[TBL] [Abstract][Full Text] [Related]
19. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
Agarwal R; Gomberg-Maitland M
Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
[TBL] [Abstract][Full Text] [Related]
20. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors.
Li M; Stenmark KR; Shandas R; Tan W
J Vasc Res; 2009; 46(6):561-71. PubMed ID: 19571576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
